Results 21 to 30 of about 3,759,163 (248)

Circulating microRNAs as potential new biomarkers for prostate cancer [PDF]

, 2013
Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics.
Bevan, C. L., J Waxman, Waxman, J, Dart, Dafydd Alwyn, A Sita-Lumsden, Waxman, J., Sita-Lumsden, A., C L Bevan, Dart, DA, Sita-Lumsden, A, Bevan, CL, D A Dart   +11 more
core   +1 more source

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

Genome Medicine, 2019
Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted ...
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H. Adomat, Dong Lin, Hui Xue, Xin Dong, Robert Shukin, Robert H. Bell, Brian McConeghy, Anne Haegert, Sonal Brahmbhatt, Estelle Li, Htoo Zarni Oo, Antonio Hurtado-Coll, Ladan Fazli, Joshua Zhou, Yarrow McConnell, Andrea McCart, Andrew Lowy, Gregg B. Morin, Tianhui Chen, Mads Daugaard, S. Cenk Sahinalp, Faraz Hach, Stephane Le Bihan, Martin E. Gleave, Yuzhuo Wang, Andrew Churg, Colin C. Collins   +32 more
doaj   +1 more source

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. [PDF]

, 2012
BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by ...
Younus, A, Stone, S, M Perry, Mesher, D, A Gutin, J S Lanchbury, Scardino, P, H Møller, A Younus, Gutin, A., J Park, Stone, S., Cuzick, J, D M Berney, Lanchbury, JS, D Mesher, Scardino, P., Mesher, D., J Cuzick, Berney, D. M., Moller, H.; id_orcid, Cuzick, J., Reid, JE, Lanchbury, J. S., Berney, DM, Fisher, G., Perry, M, Transatlantic Prostate Group, P Scardino, S Stone, Foster, C. S., Fisher, G, Møller, H, Foster, CS, Reid, J. E., G Fisher, C S Foster, Younus, A., J E Reid, Park, J., Gutin, A, Park, J, Perry, M.   +42 more
core   +1 more source

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells

Cancer Biology & Therapy, 2022
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.
Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino   +10 more
doaj   +1 more source

HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition

Frontiers in Cell and Developmental Biology, 2021
Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α).
Hao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, Christopher T. Harvey, Changhui Xue, Qiong Liu, Sadie Wiens, Sushant K. Kachhap, Tomasz M. Beer, David Z. Qian   +9 more
doaj   +1 more source

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP   +16 more
doaj   +1 more source

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer [PDF]

, 2013
<p>Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)–extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP). The mechanism
Kalna, G., Yang, Z H, Z H Yang, Leung, H.Y., Scardino, P, L B Singh, Singh, LB, H Møller, C Cooper, Cuzick, J, J Fleming, Singh, L.B., Yang, Z.H., I Ahmad, G Kalna, D M Berney, Singh, L. B., Scardino, P., Leung, H Y, Ahmad, I., Møller, H; id_orcid, J Cuzick, Berney, D. M., Cuzick, J., Møller, H., Leung, H. Y., Berney, DM, Fisher, G., Fleming, J., Cooper, C., Leung, HY, Kalna, G, P Scardino, Yang, Z. H., Berney, D.M., Fisher, G, Cooper, C, Møller, H, Ahmad, I, G Fisher, Yang, ZH, Singh, L B, Fleming, J, H Y Leung, Berney, D M   +44 more
core   +1 more source

Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]

, 2011
Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Alexey Navdaev, Eble, Johannes A., Navdaev, Alexey, Johannes A. Eble   +3 more
core   +1 more source

Cross-cultural differences in men on active surveillance’ anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study

BMC Urology, 2022
Background Men diagnosed with localized prostate cancer (PCa) on active surveillance (AS) have shown to cope with anxiety caused by living with an ‘untreated cancer’ and different factors can influence the tolerance level for anxiety in these patients ...
Paola Dordoni, Sebastiaan Remmers, Riccardo Valdagni, Lara Bellardita, Letizia De Luca, Fabio Badenchini, Cristina Marenghi, Monique J. Roobol, Lionne D. F. Venderbos   +8 more
doaj   +1 more source

Long-term outcome among men with conservatively treated localised prostate cancer. [PDF]

, 2006
Optimal management of clinically localised prostate cancer presents unique challenges, because of its highly variable and often indolent natural history.
Kattan, M W, Oliver, T, M W Kattan, Scardino, P, V Reuter, H Møller, J Eastham, Cuzick, J, Reuter, V, D Berney, Fearn, P, P Fearn, Berney, D, J Cuzick, Moller, H; id_orcid, Eastham, J, Foster, C S, Transatlantic Prostate Group, P Scardino, Fisher, G, Foster, CS, Møller, H, G Fisher, C S Foster, Kattan, MW, T Oliver   +25 more
core   +1 more source